Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha

Journal of Inherited Metabolic Disease

Volumn 33, Issue SUPPL. 3, 2010, Pages

  Tanaka, Akemi ^a   Takeda, Taisuke ^a   Hoshina, Takao ^a   Fukai, Kazuyoshi ^a   Yamano, Tsunekazu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; IMMUNOGLOBULIN E; ISOENZYME;

ADOLESCENT; ANTIBODY SPECIFICITY; BLOOD; CASE REPORT; CROSS REACTION; DRUG ERUPTIONS; DRUG SUBSTITUTION; ENZYME REPLACEMENT; ENZYMOLOGY; EOSINOPHILIA; FABRY DISEASE; FEVER; HUMAN; IMMUNOLOGY; MALE; TREATMENT OUTCOME; ARTICLE; DRUG ERUPTION;

ADOLESCENT; ALPHA-GALACTOSIDASE; ANTIBODY SPECIFICITY; CROSS REACTIONS; DRUG ERUPTIONS; DRUG SUBSTITUTION; ENZYME REPLACEMENT THERAPY; EOSINOPHILIA; FABRY DISEASE; FEVER; HUMANS; IMMUNOGLOBULIN E; ISOENZYMES; MALE; TREATMENT OUTCOME;

EID: 84897926358     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9136-0     Document Type: Article

References (20)

1. Banikazemi M, Bultas J, Waldek S et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77-86
2. Bodensteiner D, Scott CR, Sims KB et al. (2008) Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-Antibody or skin-test reactivity to the recombinant enzyme. Genet Med 10:353-358
3. Eng CM, Guffon N, Wilcox WR et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345:9-16
4. Fabry H (2002) Angiokeratoma corporis diffusum-Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatr Suppl 91(439):3-5
5. Hoffman B (2009) Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis 4:21
6. Keating GM, Simpson D (2007) Agalsidase Beta: a review of its use in the management of Fabry disease. Drugs 67:435-455
7. Lidove O, Joly D, Barbey F et al. (2007) Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of the literature. Int J Clin Pract 61:293-302
8. Linhart A, Kampmann C, Zamorano JL et al. (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228-1235
9. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589-1595
10. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750-760
11. Mehta A, Ginsberg L (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr 94(Suppl):9-10
12. Mehta A, Ricci R, Widmer U et al. (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236-242
13. Moore DF, Kaneski CR, Askari H, Schiffmann R (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258-263
14. Nagueh SF (2003) Fabry disease. Heart 89:819-820
15. Pastores GM, Boyd E, Crandall K et al. (2007) Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 22:1920-1925
16. Ramaswami U, Wendt S, Pintos-Morell G (2007) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96:122-127
17. Schaefer E, Mehta A, Gal A (2005) Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome survey. Acta Paediatr Suppl 94(447):87-92
18. Schiffmann R, Ries M, Timmons M et al. (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusión setting. Nephrol Dial Transplant 21:345-354
19. Tesmoingt C, Lidove O, Reberga A et al. (2009) Enzyme therapy in Fabry disease: severe adverse events associated with antiagalsidase cross-reactive IgG antibodies. Br J Clin Pharmacol 68:765-769
20. Zarate YA, Hopkin RJ (2008) Fabry's disease. Lancet 372:1427-1435